These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics]. Susić E Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687 [TBL] [Abstract][Full Text] [Related]
5. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Nijssen S; Florijn A; Bonten MJ; Schmitz FJ; Verhoef J; Fluit AC Int J Antimicrob Agents; 2004 Dec; 24(6):585-91. PubMed ID: 15555882 [TBL] [Abstract][Full Text] [Related]
6. Persistence of TEM-52/TEM-92 and SHV-12 extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae in Italy. Perilli M; Segatore B; Mugnaioli C; Celenza G; Rossolini GM; Stefani S; Luzzaro F; Pini B; Amicosante G Microb Drug Resist; 2011 Dec; 17(4):521-4. PubMed ID: 21970626 [TBL] [Abstract][Full Text] [Related]
7. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Ben-Ami R; Rodríguez-Baño J; Arslan H; Pitout JD; Quentin C; Calbo ES; Azap OK; Arpin C; Pascual A; Livermore DM; Garau J; Carmeli Y Clin Infect Dis; 2009 Sep; 49(5):682-90. PubMed ID: 19622043 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates. Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098 [TBL] [Abstract][Full Text] [Related]
9. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760 [TBL] [Abstract][Full Text] [Related]
10. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy. Harada S; Ishii Y; Yamaguchi K Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103 [TBL] [Abstract][Full Text] [Related]
11. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A; J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex beta-lactamase patterns including extended-spectrum enzymes. Segatore B; Setacci D; Perilli M; Franchino L; Franceschini N; Agnifili A; Rossolini GM; Amicosante G Int J Antimicrob Agents; 2004 May; 23(5):480-6. PubMed ID: 15120727 [TBL] [Abstract][Full Text] [Related]
14. Extended-spectrum beta-lactamases in North America, 1987-2006. Bush K Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():134-43. PubMed ID: 18154537 [TBL] [Abstract][Full Text] [Related]
15. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Hawkey PM Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():159-65. PubMed ID: 18154540 [TBL] [Abstract][Full Text] [Related]
16. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Hirakata Y; Matsuda J; Miyazaki Y; Kamihira S; Kawakami S; Miyazawa Y; Ono Y; Nakazaki N; Hirata Y; Inoue M; Turnidge JD; Bell JM; Jones RN; Kohno S; Diagn Microbiol Infect Dis; 2005 Aug; 52(4):323-9. PubMed ID: 16165001 [TBL] [Abstract][Full Text] [Related]
17. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Spanu T; Luzzaro F; Perilli M; Amicosante G; Toniolo A; Fadda G; Antimicrob Agents Chemother; 2002 Jan; 46(1):196-202. PubMed ID: 11751134 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection. Stürenburg E; Sobottka I; Noor D; Laufs R; Mack D J Antimicrob Chemother; 2004 Jul; 54(1):134-8. PubMed ID: 15150168 [TBL] [Abstract][Full Text] [Related]
19. [Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infection in Spain: SMART 2003 study outcomes]. Baquero F; Cercenado E; Cisterna R; de la Rosa M; García-Rodríguez JA; Gobernado M; Pérez JL; Manchado P; Martín R; Pascual A; Picazo J; Prats G; Rubio C; Snyder TA; Sanz-Rodríguez C Rev Esp Quimioter; 2006 Mar; 19(1):51-9. PubMed ID: 16688292 [TBL] [Abstract][Full Text] [Related]
20. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]